According to Britton Jimenez, from Codexis, the future of RNA therapeutics lies beyond traditional synthesis and requires a shift in manufacturing strategy toward advanced and agile platforms and sourcing.

ten23 health and dsm-firmenich have commenced a scientific collaboration to evaluate pharmaceutical-grade ingredients as potential excipients, seeking new materials to address the challenges of formulation stability and manufacturability for parenteral biologic drugs.

SPONSORED CONTENT: The IMA Active Competence Center Academy is a comprehensive e-learning platform that helps pharmaceutical manufacturers build expertise in solid dose production.

Experts from Alcami break down the latest innovations in lipid-based permeation matrices, continuous direct compression, and advanced analytical workflows designed to bring oral peptides to market safely and predictably.

As poor solubility continues to plague development pipelines, alternative biocompatible permeation enhancers are becoming increasingly beneficial for formulation scientists notes Roger Viney from ICE Pharma.

The integration of Autolomous’ autoloMATE system and Cellular Origins’ Constellation platforms aims to standardize and digitize cell therapy manufacturing within existing bioprocess infrastructure.

Through acquiring the rights to Nona Biosciences’ TfR1 BBB technology and expanding its strategic collaboration with the company, Lonza is broadening its capabilities to support customers developing next-gen CNS therapies.

The move to acquire Catalent’s Nottingham facility strengthens Codis’ integrated CDMO model, linking formulation, spray drying, and commercial-scale production within a single supply chain.

From highly water-soluble APIs to the strict constraints of personalized therapies, masking unpleasant drug tastes remains a complex engineering challenge, requiring forward-thinking downstream strategies.

The biotech, which was formerly known as EG 427, will use the funds raised in its Series C financing round to advance its lead precision genetic medicine candidate, EG110A.

Recent AI-related news is signaling a shift in the bio/pharma industry’s digital transformation from speculative molecule generation toward grounded biological context and downstream manufacturing execution.

Under the terms of the deal, Adragos Pharma will increase manufacturing capacity to supply Towa with up to 1.5 billion tablets annually to support reliable access to essential off‑patent drugs in Japan.

The appointment of three new senior business development directors across Europe and the U.S, will not only strengthen Codis’ commercial team but will also reinforce its commercial capabilities.

This latest investment by the company combines quality system integration, new high‑speed bottling and expanded cold and ambient storage to support growing U.S. packaging demand.

With an unprecedented patent cliff looming and complex modalities on the rise, executive teams must decouple capital investment risk from clinical uncertainty by embracing flexible, intensified manufacturing platforms.

Complex, targeted medicines are introducing bottlenecks into the CMC pathway, creating critical hurdles for clinical scale-up, emphasizes Henny Zijlstra from Ardena.

While DNA provides a baseline footprint for research and development, unlocking true biological complexity requires integrating dynamic multi-omics datasets, reveals Karolina Žukauskienė from VUGENE.

A new alliance between AMM and SRT will bring together senior executives and academic researchers to advance pioneering messenger RNA (mRNA) and RNA-based medicine.

As pipelines shift toward complex, high-concentration, biological formulations, traditional manufacturing models are falling short, leading to a change in outsourcing strategies, notes Mark DaFonseca from Lifecore.

Ahead of BIO 2026, FUJIFILM Biotechnologies’ Toshi Iida outlines why the industry must pivot toward harmonized, modular facility networks to eliminate manufacturing bottlenecks and secure the global medicine supply.